NICOYA年衍药业
/

NEWS & UPDATES

Follow NICOYA's progress,one milestone at a time.

Explore NICOYA's company milestones, R&D collaborations and scientific exchange with partners.

Extended-release calcifediol slows CKD progression: post-hoc analysis of a Chinese phase 3 bridging study reported at WCN 2026Read story

Latest update

Research Highlights

WCN Express: Extended-Release Calcifediol Slows Chronic Kidney Disease Progression

Reported at the World Congress of Nephrology (WCN 2026) in Yokohama, a post-hoc analysis of a Chinese phase 3 bridging study showed that among patients with secondary hyperparathyroidism (SHPT) receiving extended-release calcifediol (ERC), those whose intact parathyroid hormone (iPTH) fell by >=30% from baseline had a significantly slower decline in eGFR than non-responders (-2.4 +/- 3.8 vs -5.1 +/- 5.3 mL/min/1.73 m2, p=0.036), with no effect of sustained iPTH reduction on safety parameters - consistent with findings from US studies.

Read story ↗

All news

All news

Follow NICOYA's development and partnerships from recent updates to earlier milestones.

Extended-release calcifediol slows CKD progression: post-hoc analysis of a Chinese phase 3 bridging study reported at WCN 2026
Research Highlights

WCN Express: Extended-Release Calcifediol Slows Chronic Kidney Disease Progression

Reported at the World Congress of Nephrology (WCN 2026) in Yokohama, a post-hoc analysis of a Chinese phase 3 bridging study showed that among patients with secondary hyperparathyroidism (SHPT) receiving extended-release calcifediol (ERC), those whose intact parathyroid hormone (iPTH) fell by >=30% from baseline had a significantly slower decline in eGFR than non-responders (-2.4 +/- 3.8 vs -5.1 +/- 5.3 mL/min/1.73 m2, p=0.036), with no effect of sustained iPTH reduction on safety parameters - consistent with findings from US studies.

Read story ↗
Chinese Phase 3 Study of Extended-Release Calcifediol Presented at ASN Kidney Week 2025
Research updates

Chinese Phase 3 Study of Extended-Release Calcifediol Presented at ASN Kidney Week 2025

NICOYA’s WeChat article highlights a Chinese phase 3 study of extended-release calcifediol presented at ASN Kidney Week 2025.

Read story ↗
Two business professionals shaking hands in a life-science workplace
Company update

NICOYA and OPKO deepen their Greater China collaboration

OPKO announced a partnership update in April 2026, expanding the collaboration between EirGen and NICOYA on RAYALDEE development and commercialization in Greater China.

Read story ↗
Translucent rings representing filing and review milestones
R&D milestone

Calcifediol program reaches a China IND submission milestone

In February 2023, Nicoya notified EirGen of an IND submission to China's Center for Drug Evaluation.

Read story ↗
Amber and mineral-green forms representing regional collaboration
Partnership milestone

Greater China development and commercialization partnership begins

In 2021, OPKO announced an agreement with Nicoya Therapeutics covering the development and commercialization of RAYALDEE in Greater China.

Read story ↗